최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean chemical engineering research = 화학공학, v.55 no.2, 2017년, pp.180 - 189
김바울 (순천향대학교 의료과학대학 의약공학과) , 조민용 (순천향대학교 의료과학대학 의료과학과) , 최광진 (순천향대학교 의료과학대학 의약공학과)
Pharmaceutical co-crystals primarily to improve the solubility as well as stability of insoluble drug are to be investigated more intensively for IMDs as US FDA has reclassified co-crystal as a special case of solvates in August this year. In this study, we proposed a mechanism of indomethacin-sacch...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Indomethacin이란? | Indomethacin (IMC, Fig. 1, CAS number 53-86-1)은 일반적으로 non-steroidal anti-inflammatory drug (NSAIDs)계열로 inflammation으로부터 유도되는 종양, 강직, 통증, 열을 제거하기 위한 처방약이다. 이 약은 신체 내에서 arachidonate cascaded의 중요 효소인 COX(cyclooxygenase)를 저해해, PGs (prostaglandin)의 생산을 억제함으로써 작용을 나타낸다[6]. | |
Indomethacin의 dissolution rate나 solubility를 개선하려는 이유는? | 본 연구에서는 form α, form γ를 이용한 연구를 진행하였다. 위와 같은 API (active pharmaceutical ingredient)는 solubility가 낮으면서, 높은 permeability를 가진 Class II에 속하는약물로 물에 잘 녹지 않아, 낮은 흡수성과 생체 이용률을 가진다. 이로 인해 이러한 Indomethacin (IMC) 의 dissolution rate나 solubility를 개선하기 위해 많은 연구가 이루어지고 있다[34,35]. | |
anti-solvent crystallization의 장점은? | 이러한 결정화 공정은 cooling, evaporation, pH-controlled, anti-solvent 등의 방식을 이용하여 얻을 수 있다. 그 중 anti-solvent crystallization은 short time-consuming 방식이며, 열에 민감한 compound에도 적용할 수 있다는 장점을 가지고 있다. 이러한 anti-solvent crystallization의 기초적인 원리는 두 개의 용해도가 서로 다른 용매를 섞는 것이다. |
Chang, J. W. and Yang, D. R., "Metastable Zone Prediction Model for Industrial Crystallization," KIC News, 10(5), 25-30 (2007).
Sarma, B., Chen, J., Hsi, H.-Y. and Myerson, A. S., "Solid Forms of Pharmaceuticals: Polymorphs, Salts and Cocrystals," Korean J. Chem. Eng., 28(2), 315-322(2011).
Liu, X., Sun, D., Wang, F., Wu, Y. J., Chen, Y. and Wang, L., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined FBRM-PVM-NIR," Journal of Pharmaceutical Sciences, 100(6), 3(2011).
Lee, M.-J., Wang, I.-C., Kim, M.-J., Kim, P., Song, K.-H., Chun, N.-H., Park, H.-G. and Choi, G. J., "Controlling the Polymorphism of Carbamazepine-saccharin Cocrystals Formed During Antisolvent Cocrystallization Using Kinetic Parameters," Korean J. Chem. Eng., 32(9), 1910-1917(2015).
Genck, W., Make The Most of Antisolvent Crystallization, Chemical Processing, Article, Nov 08, 2010.
http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id713.
Surwase, S. A., Boetker, J. P., Saville, D., Boyd, B. J., Gordon, K. C., Peltonen, L. and Strachan, C. J., "Indomethacin: New Polymorphs of an Old Drug," Mol. Pharmaceutics, 10, 4472-4480 (2013).
Khomane, K. S., More, P. K., Raghavendra, G. and Bansal, A. K., "Molecular Understanding of the Compaction Behavior of Indomethacin Polymorphs," Mol. Pharmaceutics, 10, 631-639(2013).
Carpentier, L., Decressain, R., Desprez, S. and Descamps, M., "Dynamics of the Amorphous and Crystalline ${\alpha}-$ , $\gamma$ -Phases of Indomethacin," J. Phys. Chem. B, 110, 457-464(2005).
Csermely, P., Korcsmaros, T. Kiss, H. J., London, G. and Nussinov, R., "Structure and Dynamics of Molecular Networks: A novel Paradigm of Drug Discovery: A comprehensive Review," Pharmacol. Ther., 138(3), 333-408(2013).
Stegemann, S., Leveiller, F., Franchi, D., De Jong, H. and Linden, H., "When Poor Solubility Becomes an Issue: From early Stage to Proof of Concept," Eur. J. Pharm. Sci., 31(5), 249-261(2007).
Di, L., Fish, P. V. and Mano, T., Bridging Solubility Between Drug Discovery and Development., Drug Discovery Today, 486-495(2012).
Turner, J. R. Drug Discovery. In New Drug Development; Springer: New York, pp 21-34(2010).
Li, P. and Zhao, L., "Developing Early Formulations: Practice and Perspective," Int. J. Pharmaceutics, 341(1-2), 1-19(2007).
Baird, J. A., Van Eerdenbrugh, B. Taylor, L. S., A classification System to Assess the Crystallization Tendency of Organic Molecules From Undercooled Melts," J. Pharm. Sci., 2010, 99 (9), 3787-3806(2010).
Engers, D., Teng, J., Jimenez-Novoa, J., Gent, P., Hossack, S., Campbell, C., Thomson, J., Ivanisevic, I., Templeton, A., Byrn, S., Newman, A., A solid-state Approach to Enable Early Development Compounds: Selection and Animal Bioavailability Studies of an Itraconazole Amorphous Solid Dispersion," J. Pharm. Sci., 99(9), 3901-3922(2010).
Neervannan, S., "Preclinical Formulations for Discovery and Toxicology: Physicochemical Challenges," Expert Opin. Drug Metab. Toxicol., 2(5), 715-731(2006).
Hancock, B. C. and Zografi, G., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," J. Pharm. Sci., 86(1), 1-12(1997).
Laitinen, R., Lobmann, K., Strachan, C. J., Grohganz, H. and Rades, T., "Emerging Trends in the Stabilization of Amorphous Drugs," Int. J. Pharmaceutics, 453, 65-79(2013).
Bhugra, C. and Pikal, M. J., "Role of Thermodynamic, Molecular and Kinetic Factors in Crystallization From the Amorphous State," J. Pharm. Sci., 97(4), 1329-1349(2008).
Savolainen, M., Kogermann, K., Heinz, A., Aaltonen, J., Peltonen, L., Strachan, C. and Yliruusi, J., "Better Understanding of Dissolution Behaviour of Amorphous Drugs by in Situ Solid-state Analysis Using Raman Spectroscopy," Eur. J. Pharm. Biopharm., 71(1), 71-79(2009).
Wu, T., Sun, Y., Li, N., De Villiers, M. M. and Yu, L., "Inhibiting Surface Crystallization of Amorphous Indomethacin by Nano Coating," Langmuir, 23(9), 5148-5153(2007).
Alonzo, D., Zhang, G., Zhou, D., Gao, Y. and Taylor, L., "Understanding the Behavior of Amorphous Pharmaceutical Systems During Dissolution," Pharm. Res., 27(4), 608-618(2010).
Greco, K. and Bogner, R., "Crystallization of Amorphous Indomethacin During Dissolution: Effect of Processing and Annealing," Mol. Pharmaceutics, 7(5), 1406-1418(2010).
Andronis, V., Yoshioka, M. and Zografi, G., "Effects of Sorbed Water on the Crystallization of Indomethacin From the Amorphous State," J. Pharm. Sci., 86(3), 346-351(1997).
Andronis, V. and Zografi, G., "Crystal Nucleation and Growth of Indomethacin Polymorphs From the Amorphous State," J. Non-Cryst. Solids, 271(3), 236-248(2000).
Hancock, B. C., Shamblin, S. L. and Zografi, G., "Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures," Pharm. Res., 12(6), 799-806(1995).
Borka, L., "The Polymorphism of Indomethacin, New Modifications, Their Melting Behaviour and Solubility," Acta Pharm. Suec., 11, 295-303(1974).
Lin, S. Y., "Isolation and Solid-state Characteristics of a New Crystal Form of Indomethacin," J. Pharm. Sci., 81(6), 572-576 (1992).
Takiyama, H., Minamisono, T. Osada, Y. and Matsuoka, M., "Operation Design for Controlling Polymorphism in the Anti-solvent Crystallization by Using Ternary Phase Diagram," Chem. Eng. Res. Design. 88, 1242-1247(2010).
Wang, X., de Armas, H. N., Blaton, N., Michoel, A., den Mooter, G. V., "Phase Characterization of Indomethacin in Binary Solid Dispersions with PVP VA64 or Myrj 52," International Journal of Pharmaceutics, 345, 95-100(2007).
Chen, X., Morris, K. R., Griesser, U. J., Byrn, S. R. and Stowell, J. G., "Reactivity Differences of Indomethacin Solid Forms with Ammonia Gas," J. Am. Chem. Soc., 124, 15012-15019(2002).
Qi, S. and Craig, D. Q. M., "The Development of Modulated, Quasi-Isothermal and Ultraslow Thermal Methods as a Means of Characterizing the $\alpha$ to $\gamma$ Indomethacin Polymorphic Transformation," Mol. Pharmaceutics, 9, 1087-1099(2012).
Majid Saeedi, Jafar Akbari, Katayoun Morteza-Semnani, Reza Enayati-Fard, Shirin Sar-Reshteh-dar and Ala Soleymania, "Enhancement of Dissolution Rate of Indomethacin: Using Liquisolid Compacts," Iran J Pharm Res., 10(1), 25-34(2011).
Alsaidan, S. M., Alsughayer, A. A. and Eshra, A. G., "Improved Dissolution Rate of Indomethacin by Adsorbents," Drug Dev. Ind. Pharm., 24, 389-394(1998).
Chun, N.-H., Wang, I.-C., Lee, M.-J., Jung, Y.-T., Lee, S., Kim, W.-S. and Choi, G. J., "Characteristics of Indomethacin-Saccharin (IMC-SAC) Co-Crystals Prepared by an Anti-Solvent Crystallization Process," European Journal of Pharmaceutics and Biopharmaceutics, 85(3), 854-861(2013).
Wang, I.-C., Lee, M.-J., Sim, S.-J., Kim, W.-S., Chun, N.-H. and Choi, G. J., "Anti-Solvent Co-Crystallization of Carbamazepine and Saccharin," International Journal of Pharmaceutics, 450(1-2), 311-322(2013).
De Beer, T. R., Baeyens, W. R., Ouyang, J., Vervaet, C. and Remon, J. P., "Raman Spectroscopy as a Process Analytical Technology Tool for the Understanding and the Quantitative in-line Monitoring of the Homogenization Process of a Pharmaceutical Suspension," Analyst., 131(10), 1137-44(2006).
Kim, J. Y. and Kwon, K., "A Study on the Comparison of Korea GMP with PIC/S GMP for Enhancing International Competecy of Medicinal Product Quality," Yakhak Hoeji, 57(6), 432-441 (2013).
http://www.dailypharm.com/News/184408.
http://www.yonhapnews.co.kr/bulletin/2016/07/27/0200000000AKR20160727096700017.HTML?input1195m.
Kelly, A. L., Gough, T., Dhumal, R. S., Halsey, S. A., Paradkar, A., "Monitoring Ibuprofen-Nicotinamide Cocrystal Formation During Solvent Free Continuous Cocrystallization (SFCC) Using Near Infrared Spectroscopy as a PAT Tool," Int. J. Pharm., 426(1-2), 15-20(2012).
U. S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070305.pdf).
Su, M., Wang, L., Sun, H. and Wang, J. K., "FBRM and PVM Investigations of the Double Feed Semi-Batch Crystallization of 6-Aminopenicillanic Acid," Frontiers of Chemical Engineering in China, 3(3), 282-288(2009).
Liu, X., Sun, D., Wang, F., Wu, Y. J. and Chen, Y., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined Fbrm-pvm-nir," J. Pharmaceutical Sci., 100(6), (2011).
Leyssens, T., "Carine Baudry and Maria Luisa Escudero Hernandez, Optimization of a Crystallization by Online FBRM Analysis of Needle-Shaped Crystals," Org. Process Res., 413-426(2011).
Jia, C.-Y., Yin, Q.-X., Zhang, M.-J., Wang, J.-K. and Shen, Z.-H., "Polymorphic Transformation of Pravastatin Sodium Monitored Using Combined Online FBRM and PVM," Organic Process Research & Development, 12(6), (2008).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.